ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

ARS Pharmaceuticals (SPRY) posted Long-Term Investments of $24.2 million for Q2 2022, down 44.93% sequentially from $44.0 million in Q1 2022.

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022) Analysis & Trends

ARS Pharmaceuticals has reported Long-Term Investments for 2 years, with the latest figure at $24.2 million in Q2 2022.

Quarterly Long-Term Investments changed N/A year-over-year to $24.2 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $24.2 million (changed N/A YoY) and the FY2021 annual result came in at $64.8 million, changed N/A from the prior year.
Long-Term Investments slipped to $24.2 million in Q2 2022 per SPRY's latest filing, from $44.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $64.8 million in Q4 2021 and troughed at $24.2 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	372.10 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	22.17 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	ARS Pharmaceuticals	561.88 Mn	418.03 Mn	-	-

Download Data